Bragar Eagel & Squire, P.C. is Investigating Certara, Inc. on Behalf of Certara Stockholders and Encourages Investors to Contact the Firm

Law firm Bragar Eagel & Squire is investigating Certara, Inc. for potential securities law violations following the company's Q1 2026 earnings announcement. Certara reported declining services revenue (down 4% YoY to $57.2M) and bookings (down 14% YoY to $66.6M), citing softer performance from major customers and exiting its regulatory business. The stock fell 19% on the news, dropping from $6.31 to $5.13 per share on May 11, 2026.

06/19/2026, 2:11 PM • GlobeNewswire

Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Law firm Johnson Fistel is investigating Certara, Inc. (NASDAQ: CERT) on behalf of investors who suffered losses following the company's May 2026 earnings report disclosing declining services revenue and bookings, along with execution challenges. The investigation was further prompted by the announcement of CFO John Gallagher's resignation effective July 14, 2026. Investors who purchased Certara securities and experienced losses are encouraged to contact the firm.

06/18/2026, 7:15 PM • GlobeNewswire

The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It

The AI drug discovery field is shifting focus from building the most powerful models to establishing trustworthy, connected biological data foundations. MindWalk Holdings (HYFT) has positioned itself as a leader in this 'context layer' approach with its ReefIQ and LensAI platforms, reporting 52% YoY revenue growth and its first recurring platform contract. The article examines how this represents a maturation of the sector beyond initial hype, comparing MindWalk's strategy to peers like Absci, Recursion, Schrödinger, and Certara.

06/16/2026, 8:45 AM • Benzinga

CERT Investors Have Opportunity to Join Certara, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm announced an investigation into Certara, Inc. (NASDAQ: CERT) for potential securities law violations following the company's May 11, 2026 Q1 earnings report. Certara disclosed declining services revenues and bookings, attributing the weakness to softer performance from Tier 1 customers in MIDD services. The stock fell 19% on the announcement, prompting the law firm to seek shareholders who suffered losses.

05/24/2026, 2:14 PM • GlobeNewswire

CERT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

Law firm Kirby McInerney LLP is investigating Certara, Inc. for potential securities law violations following the company's Q1 2026 earnings report, which revealed a 4% decline in services revenue and 14% decline in services bookings, along with softer Tier 1 customer performance and exit from the regulatory business. The stock price fell 19% on the news.

05/18/2026, 7:00 PM • GlobeNewswire

Global Biosimulation Market Poised for Phenomenal Expansion at a CAGR of ~17% by 2034 | DelveInsight

The biosimulation market is experiencing robust growth, projected to expand from USD 4.7 billion in 2025 to USD 20 billion by 2034 at a CAGR of ~17%. Growth is driven by increasing adoption of model-informed drug development (MIDD), rising complexity of modern therapeutics, regulatory support from FDA and EMA, and the shift toward virtual clinical trials and precision medicine. North America leads the market with 44.24% share, while Asia-Pacific emerges as a major growth contributor.

04/27/2026, 1:00 PM • GlobeNewswire

Clinical Trial Software Research Report 2026: $2.5+ Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

The clinical trial software market is expected to grow from $1.32 billion in 2025 to $2.53 billion by 2030, with a CAGR of 13.8%. Growth drivers include increased digitization, adoption of AI and cloud-based solutions, virtual and decentralized trials, and enhanced data security focus. Major players are innovating with unified trial solutions and strategic acquisitions to strengthen their market positions.

04/24/2026, 4:55 AM • GlobeNewswire

Certara Strategic Business Divestiture Comes At Right Time, Says Analyst

Certara announced the sale of its Regulatory and Medical Writing business to Veristat for up to $135 million. The divestiture is expected to close in Q2 2026 and will allow the company to focus on its Model-Informed Drug Development platform. Analysts view this as strategically positive timing, with William Blair noting it removes an overhang and provides capital for reinvestment in core biosimulation platforms.

04/22/2026, 3:23 PM • Benzinga

Certara Stock Fell 23% After Earnings and This Fund Bought Up $3 Million Anyway

Kopion Asset Management purchased 327,064 additional shares of Certara (worth ~$3.37 million) during Q4, despite the stock falling 23% post-earnings. The fund views the sharp decline as a buying opportunity, noting that Certara's underlying business remains solid with 10% revenue growth and improved profitability, making it an attractive entry point for disciplined investors.

01/05/2026, 1:17 PM • The Motley Fool

Certara Appoints Jon Resnick as Chief Executive Officer

Certara announced Jon Resnick will become CEO on January 1, 2026, succeeding William Feehery. Resnick brings over 20 years of experience from IQVIA and previously worked in healthcare policy, bringing leadership expertise in health sciences and business operations.

12/11/2025, 6:00 AM • GlobeNewswire

In Silico Clinical Trials Market Size to Reach $6.68 Billion by 2032 – SNS Insider

The global In Silico Clinical Trials Market is projected to grow from $3.42 billion in 2023 to $6.68 billion by 2032, driven by AI-based modeling, regulatory support, and accelerated drug development strategies.

11/28/2025, 12:51 AM • GlobeNewswire

Certara to Participate in Upcoming Investor Conferences

Certara launches AI-powered Quantitative Systems Pharmacology (QSP) platform called Certara IQ, highlighting the company's technological innovation in drug development. The company also celebrates its scientific achievements with 200 published papers and 11 scientists recognized among top cited researchers.

10/31/2025, 8:00 AM • GlobeNewswire

Certara to Report Third Quarter 2025 Financial Results on November 6th, 2025

Certara, a biosimulation technology company, will release its third quarter 2025 financial results on November 6th, hosting a conference call at 5:00 PM ET for investors.

10/10/2025, 8:00 AM • GlobeNewswire

Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Submissions Faster

Certara introduces Pinnacle 21 Enterprise Plus, a software solution that helps clinical and statistical programmers efficiently create and manage data specifications for regulatory submissions, promising a 50% reduction in time spent drafting mapping specifications.

09/04/2025, 8:00 AM • GlobeNewswire

Biosimulation Market to Attain USD 18.97 Billion by 2034, Rising at 16.9% CAGR

The global biosimulation market is expected to grow from USD 3.97 billion in 2024 to USD 18.97 billion by 2034, with a CAGR of 16.9%. North America currently dominates the market, driven by technological advancements and increasing research in drug development and discovery.

08/18/2025, 11:00 AM • GlobeNewswire